CGBIO, a South Korea-based company, earned the FDA’s investigational device exemption approval for its Novosis putty for spinal fusions.
The bone graft incorporates rhBMP-2 and is designed to enhance high-density bone formation and minimize ectopic bone growth, according to a news release. The rhBMP-2 protein in Novosis is manufactured by a strategic partner of CGBIO.
The FDA’s IDE approval opens up the opportunity to study the bone graft in spinal fusions in the U.S.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
